Press Releases

Opna Bio Showcases Multi-Functional Degraders with Potent Anti-Myeloma Activity and Encouraging Spleen Reductions in Patients with Myelofibrosis Treated with OPN-2853 and Ruxolitinib

Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH)

Opna Bio Announces 2025 ASH Presentations Highlighting Preclinical Data from Novel Protein Degrader Program and Updated Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Advanced Myelofibrosis

Phase 1 Clinical Trial with OPN-6602 in Multiple Myeloma Actively Enrolling Patients

Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma

OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma

Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis

Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies

Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma

Opna Announces ASH abstracts 2024

Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor

Appoints Axel Bolte, MBA, MSc to Board Director and Stephanie Oestreich, PhD, MPA to Board Observer

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting

OPN-6602 Expected to Begin Phase 1 Clinical Study in Multiple Myeloma in Summer 2024

Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs

Broad Drug Portfolio Targets Fragile-X Mental Retardation Protein (FMRP) in Cancer, Bromo and Extra Terminal (BET) Domain Proteins, Colony-stimulating Factor 1 Receptor (CSF1R), and Additional Cancer Drivers.

Seminal Research on FMRP’s Emerging Role in Cancer Published in Science.